FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2575559568> ?p ?o ?g. }

• W2575559568 abstract "Abstract Acquired von Willebrand (AvWD) disease is a relatively rare bleeding disorder and since the initial description, fewer than 300 cases of AvWD have been reported. The most frequently observed association is with dysproteinemias such as monoclonal gammopathy of undetermined significance (MGUS) and plasma cell proliferative disorders such as Waldenstroem macroglobulinemia and multiple myeloma. Other hematological diseases associated with AvWD have been reported including lymphoproliferative and myeloproliferative disorders. We report the case of a 59 year old male patient with an AvWD associated with a chronic lymphocytic leukemia. In November 2000 this patient was diagnosed with a B cell chronic lymphocytic leukemia (CLL). Because of an initial Binet-Stage A no specific therapy was initiated. In October 2003 the CLL progressed to Binet-Stage B and molecular examinations revealed an unfavorable risk profile with a 11q22.3-q23.1 deletion and an unmutated IgVH gene status. Because of the presence of an HLA-identical brother the patient was enrolled into a pilot study of allogeneic stem cell transplantation following conditioning with fludarabine and cyclophosphamid in patients with high-risk chronic lymphocytic leukemia. Four cycles of fludarabine and cyclophosphamide were given prior to allogeneic stem cell transplantation and induced a partial remission. Since 2000 the patient reported a new clinical bleeding tendency, presenting mainly as frequent epistaxis. Further laboratory investigations showed a prolonged activated partial thromboplastin time (50 sec.) and a reduced plasma von Willebrand factor (vWF) antigen and vWF activity of 6% and 2%, respectively. This was accompanied by a reduced Factor VIII activity of 14% (factor IX-, XI-, XII- activity > 100%, respectively; lupus anticoagulant assay negative; immunofixation negativ). A vWF multimer analysis showed selective decrease in the high-molecular-weight multimers as seen in type II congenital vWD. The reduced intensity conditioning (RIC) regimens consisted the following combination: Fludarabine 30mg/m² /d (=150mg/m² total dose) and Cyclophosphamide 500mg/m² /d (=2500mg/m² total dose) (day -7 through day -3), GVHD prophylaxis with Cyclosporin A (CsA) and mycophenolate mofetil (MMF). A therapeutic trial of desmopressin (DDAVP) was insufficient and therefore a continuous infusion of the factor VIII/vWF concentrate (Haemate® P; Aventis Behring) was administered from the start of conditioning until platelet recovery. Under this regimen no bleeding complication was observed, neither spontaneously nor during intensive procedures. In accordance with previous reports of replacement therapy in AvWD we observed a shortened half-life of the vWF. On day 30 after allogenic hematopoietic stem cell transplantation we observed for the first time a normalization of the activated partial thromboplastin time followed by a gradual increase of the vWF antigen and activity. On day 60 we were able to document the normalization of both the vWF antigen and activity and the vWF multimer analysis. This nomalisation was coincident with the establishment of a complete donor chimerism for the first time. We therefore believe that this case shows a form of AvWD associated with chronic lymphocytic leukemia and its reversal by treatment of the underlying disease by allogeneic hematopoietic stem cell transplantation. Figure Figure" @default.
• W2575559568 created "2017-01-26" @default.
• W2575559568 creator A5002578778 @default.
• W2575559568 creator A5004780644 @default.
• W2575559568 creator A5006360930 @default.
• W2575559568 creator A5015463629 @default.
• W2575559568 creator A5037266259 @default.
• W2575559568 creator A5071353833 @default.
• W2575559568 creator A5089395073 @default.
• W2575559568 date "2004-11-16" @default.
• W2575559568 modified "2023-09-27" @default.
• W2575559568 title "Reversal of Acquired von Willebrand Disease after Allogeneic Hematopoietic Stem Cell Transplantation in a Patient with High Risk Chronic Lymphocytic Leukemia." @default.
• W2575559568 doi "https://doi.org/10.1182/blood.v104.11.4014.4014" @default.
• W2575559568 hasPublicationYear "2004" @default.
• W2575559568 type Work @default.
• W2575559568 sameAs 2575559568 @default.
• W2575559568 citedByCount "1" @default.
• W2575559568 countsByYear W25755595682019 @default.
• W2575559568 crossrefType "journal-article" @default.
• W2575559568 hasAuthorship W2575559568A5002578778 @default.
• W2575559568 hasAuthorship W2575559568A5004780644 @default.
• W2575559568 hasAuthorship W2575559568A5006360930 @default.
• W2575559568 hasAuthorship W2575559568A5015463629 @default.
• W2575559568 hasAuthorship W2575559568A5037266259 @default.
• W2575559568 hasAuthorship W2575559568A5071353833 @default.
• W2575559568 hasAuthorship W2575559568A5089395073 @default.
• W2575559568 hasConcept C126322002 @default.
• W2575559568 hasConcept C203014093 @default.
• W2575559568 hasConcept C2776364478 @default.
• W2575559568 hasConcept C2776391228 @default.
• W2575559568 hasConcept C2776694085 @default.
• W2575559568 hasConcept C2776755627 @default.
• W2575559568 hasConcept C2777408962 @default.
• W2575559568 hasConcept C2777938653 @default.
• W2575559568 hasConcept C2778461978 @default.
• W2575559568 hasConcept C2779263901 @default.
• W2575559568 hasConcept C2911091166 @default.
• W2575559568 hasConcept C71924100 @default.
• W2575559568 hasConcept C90924648 @default.
• W2575559568 hasConceptScore W2575559568C126322002 @default.
• W2575559568 hasConceptScore W2575559568C203014093 @default.
• W2575559568 hasConceptScore W2575559568C2776364478 @default.
• W2575559568 hasConceptScore W2575559568C2776391228 @default.
• W2575559568 hasConceptScore W2575559568C2776694085 @default.
• W2575559568 hasConceptScore W2575559568C2776755627 @default.
• W2575559568 hasConceptScore W2575559568C2777408962 @default.
• W2575559568 hasConceptScore W2575559568C2777938653 @default.
• W2575559568 hasConceptScore W2575559568C2778461978 @default.
• W2575559568 hasConceptScore W2575559568C2779263901 @default.
• W2575559568 hasConceptScore W2575559568C2911091166 @default.
• W2575559568 hasConceptScore W2575559568C71924100 @default.
• W2575559568 hasConceptScore W2575559568C90924648 @default.
• W2575559568 hasLocation W25755595681 @default.
• W2575559568 hasOpenAccess W2575559568 @default.
• W2575559568 hasPrimaryLocation W25755595681 @default.
• W2575559568 hasRelatedWork W2023136491 @default.
• W2575559568 hasRelatedWork W2120351292 @default.
• W2575559568 hasRelatedWork W2137804513 @default.
• W2575559568 hasRelatedWork W2161866812 @default.
• W2575559568 hasRelatedWork W2374391184 @default.
• W2575559568 hasRelatedWork W2593968947 @default.
• W2575559568 hasRelatedWork W2801454081 @default.
• W2575559568 hasRelatedWork W2946618690 @default.
• W2575559568 hasRelatedWork W3123349251 @default.
• W2575559568 hasRelatedWork W2418979794 @default.
• W2575559568 isParatext "false" @default.
• W2575559568 isRetracted "false" @default.
• W2575559568 magId "2575559568" @default.
• W2575559568 workType "article" @default.